Back to News
Market Impact: 0.45
MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination
Source: Business Wire
Healthcare & BiotechRegulation & LegislationCorporate Guidance & Outlook
MaaT Pharma said it is updating the potential development plan for MaaT013 (Xervyteg®) after the European Medicines Agency's CHMP issued a negative opinion following re-examination. The setback materially reduces near-term regulatory approval prospects for the cancer therapy and creates uncertainty around its future development pathway.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly negative
Sentiment Score
-0.60
Ticker Sentiment
MAAT-0.85
More News
- Google's Gemini becomes latest AI model to break out and hack computer systems
- Warren Buffett stepping down as chairman of Berkshire Hathaway: 'Father Time always wins'
- After threatening to seize Greenland by force, Trump agrees to leave it with Denmark and boost military presence. ‘We will be very protective of it!’
- Google’s Gemini AI hacks 3 companies in security test, then stops
- American, United and Southwest are all cutting ‘marginal routes’ as jet fuel prices spike
- Exclusive-Anthropic considers releasing new AI model ahead of IPO, sources say
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- How to Write an Investment Memo with AI: A Decision-Record Template
- Best AI to Write Earnings Notes for Sell-Side Analysts